Amgen deal: A significant step forward
The strategic collaboration with Amgen provides further validation of Nuevolution’s Chemetics drug discovery platform. With up to $410m per development programme and a tiered royalty rate, the deal could generate significant value in the coming years. Cash of c SEK176m ($19.4m) at 30 September 2016, along with revenue from collaborations and licensing agreements, will enable Nuevolution to continue to expand its internal pipeline. We anticipate its lead internal candidate RORγt and possibly another internal candidate to be out-licensed in the next six months, while one further Amgen-style partnership could be formed by the end of 2017.Nuevolution AB (publ). Nuevolution AB is a Sweden-based biopharmaceutical company working to develop future medicine for the treatment of cancer and inflammatory diseases. The Company's business is conducted through its wholly owned subsidiary, Nuevolution A/S.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.